The Nissen/Fleming Solution For ‘Firewalled’ CV Data Disclosures
Executive Summary
Framework described by Cleveland Clinic’s Nissen specifies which employees within a sponsor have access to detailed interim results from outcomes trials and the recordkeeping requirements and technology restrictions associated with that access.
You may also be interested in...
Orexigen’s Big Plans On Hold As FDA Hashes Out Post-Marketing Requirements
Weight loss drug Contrave delayed by three months while sponsor and agency discuss how to handle data transparency for ongoing cardiovascular outcomes trial.
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.
Puberty Blockers: FDA's Califf Asked If REMS, Boxed Warning Against Off-Label Use In The Works
FDA Commissioner Robert Califf tells House appropriations subcommittee chair the agency will 'consider any information that may be available' on off-label use of puberty blockers for gender dysphoria before making a regulatory decision.